Orthocell Treats First Patient in US Military Network Just 2 Days After Approval
Orthocell completes first Remplir surgery in US military hospital network
Orthocell has announced the completion of its first surgical case using Remplir within the US Department of Defense (DoD) and Veterans Affairs (VA) hospital network. The procedure was performed at a military base hospital in Ohio just two days after the company received approval to supply the device across these systems on 15 April 2026, with the surgery completed by 17 April 2026.
The milestone demonstrates the company’s capacity to rapidly convert regulatory access into clinical use. The approval provides Orthocell with access to approximately 221 hospitals across the US military and veteran healthcare systems, comprising 51 DoD military hospitals and 170 VA medical centres nationwide.
The swift transition from approval to first surgical case validates Orthocell’s commercial execution capability and signals early surgeon engagement within trauma-focused military healthcare systems. The company’s existing US distributor network, which spans 17 states, is now positioned to support both military and civilian hospital channels.
When big ASX news breaks, our subscribers know first
What is Remplir and why does peripheral nerve repair matter?
Remplir is a collagen-based medical device designed for peripheral nerve reconstruction. Peripheral nerve injuries can result in loss of motor function and sensation, presenting significant clinical challenges particularly in trauma settings.
The device addresses a critical need in military and veteran healthcare systems, which manage some of the most challenging trauma cases. Peripheral nerve damage from combat injuries, accidents, or surgical complications can lead to permanent functional impairment if not properly reconstructed.
Military and veteran hospitals therefore represent a strategically important market segment for Remplir. These facilities treat complex nerve injuries where the device’s clinical application is most relevant, providing both a revenue opportunity and a validation pathway for broader commercial adoption across civilian healthcare systems.
Commercial momentum across the US hospital system
Distribution network positioned for scale
Orthocell has established a US distributor footprint across 17 states to support Remplir’s commercial rollout. These distribution partners provide surgeon onboarding and in-theatre case support, enabling the rapid clinical adoption demonstrated by the Ohio procedure.
The same distribution network will now support uptake across both DoD/VA facilities and the broader US hospital system. The company has already recorded initial Remplir sales in the US market, with the DoD/VA approval expanding the addressable hospital network significantly.
| Network | Number of Facilities |
|---|---|
| DoD Military Hospitals | 51 |
| VA Medical Centres | 170 |
| Total | 221 |
The distribution infrastructure is designed to scale efficiently as case activity increases across multiple hospital channels. With procurement approvals now in place, the focus shifts to surgeon education and case support to drive repeat usage within the military and veteran networks.
Management commentary
Paul Anderson, Managing Director
“We are extremely pleased to see Remplir progress to its first surgical case within the U.S. DoD and VA hospital network so soon after approval, validating our commercial strategy, surgeon engagement, and distribution capability.”
Anderson also emphasised the clinical relevance of the milestone, noting that military and veteran healthcare systems manage some of the most challenging trauma cases. He described the early surgical uptake as an encouraging signal as the company continues to expand activity across these hospitals.
The rapid progression from approval to clinical use demonstrates both the strength of Orthocell’s commercial execution and the clinical demand for peripheral nerve reconstruction solutions within trauma-focused healthcare systems.
The next major ASX story will hit our subscribers first
Investment outlook and next steps
The DoD/VA milestone forms part of Orthocell’s broader US commercialisation strategy for Remplir. The company will continue working with distribution partners and surgeon networks to drive further uptake across military, veteran, and civilian hospital channels.
Key focus areas for the commercial rollout include:
- Expanding hospital access across DoD, VA, and civilian systems
- Growing surgeon engagement and increasing case activity
- Distributor network supporting both military and commercial hospital channels
The speed of conversion from approval to first surgical case demonstrates execution capability that extends beyond regulatory achievements. The ability to translate procurement access into revenue-generating clinical use within two days validates both the commercial infrastructure and the clinical value proposition.
Revenue potential now extends across 221 military and veteran hospitals in addition to the broader US civilian hospital network. With distribution partners positioned across 17 states and initial sales already recorded, the company has established the operational foundation to scale case activity as surgeon adoption increases.
The military and veteran healthcare market also provides strategic value beyond immediate revenue. Successful clinical outcomes and case activity within DoD/VA systems can serve as validation for broader hospital adoption, potentially accelerating uptake across civilian trauma and reconstructive surgery programmes.
Get Healthcare Breakthroughs Before the Market Moves
Join 20,000+ investors receiving FREE ASX healthcare alerts within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start getting breaking news and expert coverage delivered straight to your inbox.